BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32987483)

  • 1. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
    Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A;
    Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H; Zhou H; Zhang Z; Geng C; Chen W
    Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
    Wang H; Li JY; Sun C; Zhou X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
    Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
    J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
    Katodritou E; Kastritis E; Dalampira D; Delimpasi S; Spanoudakis E; Labropoulou V; Ntanasis-Stathopoulos I; Gkioka AI; Giannakoulas N; Kanellias N; Papadopoulou T; Sevastoudi A; Michalis E; Papathanasiou M; Kotsopoulou M; Sioni A; Triantafyllou T; Daiou A; Papadatou M; Kyrtsonis MC; Pouli A; Kostopoulos I; Verrou E; Dimopoulos MA; Terpos E
    Am J Hematol; 2023 May; 98(5):730-738. PubMed ID: 36869876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
    Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Plasma Cell Leukemia: Identity Card 2016.
    Musto P; Simeon V; Todoerti K; Neri A
    Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Characteristics and Survival Analysis of Patients with Plasma Cell Leukemia].
    Wang SF; Qin XQ; Guo QH; Wang JY; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):693-698. PubMed ID: 37356928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
    Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
    Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
    Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
    Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].
    Dou XL; Liu RX; Liu Y; Peng N; Wen L; Wu Y; Li Q; Zhong YP; Zhou X; Liao AJ; Jiang HN; Ma XJ; Dong HH; Fan SJ; Zhao YQ; Hu DH; Lu J
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):499-506. PubMed ID: 38317361
    [No Abstract]   [Full Text] [Related]  

  • 17. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I treat plasma cell leukemia.
    van de Donk NW; Lokhorst HM; Anderson KC; Richardson PG
    Blood; 2012 Sep; 120(12):2376-89. PubMed ID: 22837533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
    D'Arena G; Valentini CG; Pietrantuono G; Guariglia R; Martorelli MC; Mansueto G; Villani O; Onofrillo D; Falcone A; Specchia G; Semenzato G; Di Renzo N; Mastrullo L; Venditti A; Ferrara F; Palumbo A; Pagano L; Musto P
    Ann Oncol; 2012 Jun; 23(6):1499-502. PubMed ID: 22039089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.